In view of the known association of vascular disease with increasing age, we have conducted an analysis of hemostatic system activity with respect to perturbations induced by aging phenomena. We have utilized an immunochemical assay for prothrombin fragment F1+2 to quantify Factor Xa activity upon prothrombin in the plasma of 199 healthy males between the ages of 42 and 80. The levels of F1+2 in this population generally increased as a function of age (P < 0.0001). The metabolic behavior of this marker was determined in 10 individuals > 65 yr of age with varying levels of F1+2, which ranged from 1.28 to 5.85 nM. The elevations in the concentration of this component were not due to diminished clearance of the fragment. Radioimmunoassays for fibrinopeptide A (FPA) and the protein C activation peptide (PCP) were subsequently employed to measure thrombin activity upon fibrinogen and thrombin-thrombomodulin activity upon protein C, respectively, in 82 members of this population ranging in age from 42 to 80. Significant positive correlations were again observed between increasing age and the level of F1+2 (P < 0.0001) as well as FPA (P < 0.01) and PCP (P < 0.002). The results of this cross-sectional study indicate that many apparently normal males of increasing age with normal immunologic levels of antithrombin III and protein C exhibit a biochemical defect that denotes the presence of an acquired prethrombotic state.
Introduction
Numerous investigators have attempted to determine whether a relationship exists between abnormalities in the hemostatic mechanism and the occurrence of vascular disease in populations undergoing the normal aging process. The major difficulty encountered in unravelling this puzzle has been a lack of reliable techniques for quantifying pertinent changes in blood coagulability. It should be noted that previous methods for monitoring these processes have been directed at measuring the levels of zymogens, inhibitors, or substrates of the hemostatic system (1) (2) (3) (4) (5) . Unfortunately, these molecular species are present in large excess within the blood. Only a small percentage of the zymogens are converted to active enzymes under in vivo conditions (6) (7) (8) . This level of activated intermediate is responsible for only minimal depletion of inhibitors and negli-gible conversion of substrates to final products. Thus, attempts to define an acquired prethrombotic state by quantifying the concentrations of zymogens, inhibitors, and substrates have yielded ambiguous results.
During the past 15 yr, a number ofimportant aspects ofthe hemostatic mechanism have been elucidated. Based upon this information, a series of highly sensitive and specific RIAs have been developed which can quantify the activities of various steps of the hemostatic mechanism in vivo at the subnanomolar level. We have established assays for the F1+2 fragment and the protein C activation peptide (PCP)' that measure the cleavage of the prothrombin molecule by Factor Xa (9, 10) and the scission of protein C by the thrombin-thrombomodulin complex (8) , respectively. Nossel and co-workers (1 l1-13) have developed a similar assay for fibrinopeptide A (FPA) that monitors the cleavage of fibrinogen by thrombin. We have previously utilized the RIAs for F1+2 and FPA to demonstrate that substantial elevations in Factor Xa activity but not thrombin activity regularly occur in the blood of asymptomatic individuals with hereditary deficiencies of antithrombin III (7) or protein C (Bauer, K. A., A. W. Broekmans, R. M. Bertina, J. Conard, M. Horellou, M. M. Samama, and R. D. Rosenberg. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Submitted for publication), disorders known to be correlated with the subsequent development of thrombosis.
In this communication, we have utilized the preceding immunochemical techniques to demonstrate that many healthy individuals exhibit excessive activity oftheir hemostatic mechanisms in association with the aging process in the absence of clinically overt vascular disease.
major subpopulation that has remained healthy. The social characteristics of this population reveal that they come from a slightly higher socioeconomic level than the general population. In addition, Blacks are somewhat underrepresented within the sample. The population sample was initially chosen to obtain a geographically stable group and <1% of patients per year have become unavailable for further investigation due to all causes, including death.
Individuals in the Normative Aging Study are examined once every 5 yr up to the age of 52 and once every 3 yr thereafter. This procedure includes a detailed history, a complete physical examination, chest x ray, pulmonary function tests, and electrocardiogram, as well as standard blood and urine tests. The latter analyses include complete blood count, liver and kidney function tests, glucose tolerance test, lipid profile, and protein electrophoresis. Diseases uncovered during the examination as well as those occurring between visits are recorded by standardized techniques. Furthermore, psychosocial data of various types are prospectively collected during the Normative Aging Study. These include the incidence and intensity of smoking as well as the level of physical activity of the participants.
Collection ofblood samples. Venipunctures were performed atraumatically in the morning on fasting subjects with 19-or 21-gauge butterfly infusion sets using a two-syringe technique. Patients were instructed not to take aspirin or aspirin-containing compounds for a minimum of I wk before sample collection. Blood samples were drawn into plastic syringes preloaded with the appropriate solutions, including the following. (a) For immunologic measurements ofantithrombin III, protein C, and prothrombin, 3.8% (wt/vol) sodium citrate was employed; the ratio of anticoagulant to blood used was 0.1:0.9 (vol/ vol). (b) "F1+2 anticoagulant": 38 mM citric acid, 75 mM sodium citrate, 136 mM dextrose, 6 mM EDTA, 6 mM adenosine, and 25 U/ml heparin. The ratio of anticoagulant to blood employed was 0.2:1.0 (vol/vol). (c) "FPA anticoagulant": This preparation was provided by Mallinckrodt, Inc., St. Louis, MO. The ratio of anticoagulant to blood used was 0.1:0.9 (vol/vol). After collection of blood samples, plasma fractions were obtained by centrifugation at 4VC for 15 min at 1,600 g and stored at -80'C before use.
A normal plasma pool was constructed by pooling equal volumes of plasma from 30 control subjects. This population consisted of healthy laboratory and medical personnel between the ages of 20 and 40 who gave a negative history for bleeding as well as thrombosis, and were not taking any medications at the time of sample collection.
Processing ofplasmafor PCP RIA. The PCP in 6-12 ml of plasma was extracted from other plasma constituents and concentrated -10-fold as outlined previously (8) . The larger proteins were initially precipitated by adding 0.1 vol of7 M perchloric acid to 1 vol ofplasma. After 15 min of incubation in an ice bath, the samples were centrifuged at 27,000 g for 20 min at 4°. To salt out the residual perchlorate ions, we poured the supernatant fluid into a centrifuge tube and a sufficient amount ofa solution of 3.5 M potassium hydroxide was added to raise the pH to > 7. After a second centrifugation, the supernatant was acidified with an amount of 10% (vol/vol) phosphoric acid sufficient to lower the pH of the solution to < 3. A Sep-Pak C18 cartridge (Waters Associates, Milford, MA) was then washed with 5 ml of 80% (vol/vol) methanol followed by 5 ml of 0.1% (vol/vol) phosphoric acid. The sample was applied to the cartridge and the matrix was washed with 4 ml ofdistilled water. The peptide was subsequently eluted with 4 ml of 80% (vol/vol) with Tris-buffered saline. The resultant precipitates were quantified for 1251 counts.
In the PCP RIA, we have observed that the average recovery of added dodecapeptide in the extraction procedure is extremely constant at -60% and have elected to not divide the values obtained by the fractional recovery. Therefore, the levels of PCP cited for normal individuals are lower than previously reported (8) .
'31'-F,+2 preparation and turnover studies. Human F1+2 was purified from 2 liters of fresh frozen plasma obtained from four healthy donors who had been carefully screened for hepatitis and acquired immune deficiency syndrome. The plasma was allowed to warm to 24°C and clotting was initiated by the addition of CaC12 (final concentration, 32.4 mM). After 90 min of incubation, the clot was removed, heparin (final concentration, 1 U/ml) was added, and the suspension was stirred for an additional 5 min. Subsequently, F1+2 was isolated from the sera by DEAE-cellulose batch adsorption-elution and hydroxylapatite chromatography as described by Aronson et al. (17) . Examination of a series of fractions eluted from hydroxylapatite with a potassium phosphate concentration of 0.35-0.45 M, revealed that > 90% of the resultant material was F1+2 as judged by the SDS gel electrophoretic technique of Laemmli (18) . To remove minor higher and lower molecular weight components that migrated at rates similar to those of prothrombin and F1, respectively, 2 mg of F1+2 in 15 ml of 0.02 M Tris-HCl, 0.05 M NaCl, pH 7.5, were filtered at 20 ml/h through a column of heparin-Sepharose (0.8 X 13 cm) equilibrated with the same buffer. The heparin-Sepharose was sterilized during its preparation, and had not previously been used for any other purpose. The matrix was then washed with the above buffer. This procedure was conducted at 4°C. The recovery of F1+2 by absorbance measurements averaged 90% of the total amount applied to the column. Analysis of the resultant product by SDS gel electrophoresis confirmed that the minor contaminating species had been eliminated. The overall yield from 2 liters of plasma averaged 3.6 mg. All buffers were made in sterile, pyrogen-free water, and all glassware had been autoclaved before use.
Radiolabeling of F,+2 was accomplished by the method of Greenwood et al. ( 16) utilizing 15lg ofF1+2 and 0.6 mCi ofcarrier free Na'311 (New England Nuclear). Upon completion of the iodination, human serum albumin (Cutter Biological, Berkeley, CA) was added to the reaction mixture (final concentration, 10 mg/ml). Separation of free iodide from labeled protein was achieved by filtration of samples at 15 ml/h through a sterile column (0.8 X 26 cm) of Sephadex G-25 (Pharmacia Fine Chemicals, Piscataway, NJ) equilibrated with 0.1 M potassium phosphate, pH 7.0. Fractions of 0.5 ml were collected in sterile plastic tubes with screw caps, and those within the first peak ofradioactivity were examined with respect to their ability to be precipitated with 10% (wt/vol) TCA and specific F1+2 antisera. Fractions were pooled in which the labeled material was > 95% precipitable with TCA and > 80% immunoprecipitable by specific F1+2 antisera. This material was frozen at -80'C and utilized within 4 d ofpreparation. Before intravenous injection, the iodinated F1+2 preparation was brought to a final volume of 3-5 ml in sterile 0.9% (wt/vol) NaCl containing human serum albumin (final concentration, 2 mg/ml) and passed through a 0. 22 Analysis ofdata. Estimation of relative immunoreactivity, computation of the slopes of the dose-response curves, as well as determinations ofthe various associated indices were obtained by a least-squares fit of the RIA results to a "four parameter" model as described by Rodbard (20, 21) . Statistical analyses of data were conducted by standard techniques (22) . In most instances, the means are provided with associated standard deviations.
Results
We have measured the levels of prothrombin activation fragment F1+2 in the plasma of 199 healthy male participants of the Normative Aging Study between the ages of 42 and 80. This population was constructed by carefully screening the medical records of Normative Aging Study participants to exclude those individuals who had developed coexistent medical conditions (i.e., venous or arterial thrombotic disease, heart disease, peripheral vascular disease, hypertension, diabetes, cancer, renal disease, liver dysfunction, etc.) that might cause alterations in hemostatic system activity as measured by our RIAs. A scattergram with associated mean values for seven different age groups is presented in Fig. 1 (Table II) . Plasma radioactivity measurements in these individuals were plotted against time; 131I-F1+2 plasma radioactivity is described by a two-exponential curve, Cle-r't + C2e-r2 (23) . The fractional breakdown rate, kB (h-'), was calculated from [Cl/r1 + C2/r2]'-(24).
Whereas some differences in fractional breakdown rates were observed between the various individuals, a significant relationship between this parameter and the plasma level of F1+2 was not observed (P > 0.10). Therefore, the elevations in the concentration of this marker in these people were not due to diminished clearance of the fragment. We have observed however that the fractional breakdown rate, kB, in 10 subjects under age 50 (mean age, 32.6±11.3) is 0.3 10 h-1±0.06. While this value is somewhat greater than that observed in the sub- jects over age 65 (P < 0.05), it is apparent that this difference in clearance rates cannot make a significant contribution to the greater than twofold elevations in F1+2 levels seen in many aged subjects.
The preceding data indicate that many apparently healthy individuals undergoing the normal aging process have excessive plasma Factor Xa activity as measured by the F1+2 assay.
We next undertook more detailed studies ofhemostatic system activity in Normative Aging Study participants in an attempt to determine the nature of the defect leading to elevated F1+2 levels. The study population consisted of 82 healthy males derived from the original population of 199 subjects who consented to visiting our research laboratory for further investigation. The plasma levels of F1+2, FPA, and PCP were quantified by RIA and plotted as a function ofage (Fig. 2) . Measurements of antithrombin III, protein C, and prothrombin antigen were also performed (Table III) . Significant positive correlations were again noted between increasing age and the level of F1+2 (r = 0.461; P < 0.0001) as well as FPA (r = 0.296; P < 0.01) and PCP (r = 0.346; P < 0.002). The levels ofantithrombin III, protein C, and prothrombin antigen did not display statistically significant changes with increasing age.
It should be noted that five patients with varying ages had FPA values over 3.5 nM (Fig. 2 B) . The mean F1+2 and PCP levels in this cohort were 2.11 nM±0.64 and 1.66 pM±0.78, respectively. Given the lack of concordance of these measurements, it is possible that the elevated FPA measurements in these individuals were produced during the venipuncture procedure. We have therefore reanalyzed our data after excluding these five people and a highly significant correlation was again noted between FPA and age (r = 0.395; P < 0.0005). We have obtained additional specimens for assay from nine Normative Aging Study participants within a half year of the initial sampling to demonstrate that a given plasma level of FPA or PCP represents a stable parameter that is characteristic of a particular individual at a given point in time (Table I) . As was the case for F1+2 levels, the levels of these species were statistically indistinguishable from those obtained initially (for FPA, P> 0.05; for PCP, P> 0.10).
To examine the interrelationships among F1+2, FPA, PCP, antithrombin III, protein C, and prothrombin, we correlated the simultaneous levels of the various species in the blood of these 82 individuals. There were no statistically significant correlations observed between the levels of F1+2 and FPA, PCP, antithrombin III, protein C, or prothrombin. A signifi- '3I1-F,+2 plasma radioactivity is described by a two-exponential curve, Ce"rt + C2er2t (23) . The fractional breakdown rate, kB (h-'), was calculated from (C1/r, + C2/r2)-' (24) . *Plasma F1+2 levels cited represent mean of determinations obtained at different time points. 
Discussion
A number of highly sensitive and specific immunologic assays have been developed to quantify the activity of various steps of the hemostatic mechanism in vivo (8-13). The study of agingrelated changes in blood coagulation however has been limited to the monitoring of alterations in the levels of platelet release proteins such as beta-thromboglobulin and platelet factor 4 (25-28). Zahavi et al. (29) have observed significant elevations in the levels of these two alpha-granule proteins with increasing age. This age-dependent difference was most apparent in elderly females. Two other groups of investigators (30, 31) have obtained similar results in smaller numbers of patients. It is unclear, however, whether the correlations observed are due to increased activity of the coagulation mechanism, increased destruction of platelets, or decreased catabolic rates of the platelet release proteins.
We have previously evaluated the utility ofimmunochemical techniques which measure the extent of prothrombin activation and thrombin generation in vivo as markers of the prethrombotic state. The populations chosen for study were asymptomatic patients with inherited deficiencies of either Data are mean±SD. *F,+2 levels were significantly elevated in subjects 2 70 yr of age as compared with those in groups < 50 yr (P < 0.001) or 50-69 yr (P < 0.02). *PCP levels were significantly elevated in subjects 2 70 yr as compared with those in groups < 50 yr (P < 0.01) or 50-69 yr (P < 0.05).
Aging and the Hemostatic Mechanism 37. Significant increments in Factor Xa activity but not thrombin activity also were observed to regularly occur in the blood of these subjects as compared with an age-matched control group. These patients were also noted to have significantly reduced plasma levels of PCP. Based upon the above studies, it would appear that malfunction of the endogenous heparin-antithrombin III and/or protein C-thrombomodulin mechanisms will result in excessive generation of thrombin well before the development of overt thrombotic disease.
In view of the known association of vascular disease with increasing age, we have conducted a detailed analysis of hemostatic system activity with respect to perturbations induced by aging phenomena. None of these individuals exhibited an immunochemical deficiency of either antithrombin III or protein C. Our investigation reveals a highly significant positive correlation between increasing age and the plasma levels of F1+2. Metabolic turnover studies of '311-labeled F1+2 in these subjects indicate that elevations in concentration of the fragment were not due to diminished clearance ofthis component.
We also observed statistically significant elevations in the levels of FPA and PCP with increasing age. However, we were unable to establish direct correlations between these parameters and the F1+2 measurements. It should be noted that the magnitude of the FPA and PCP elevations between older and younger subjects was considerably smaller than was the case for F1+2 values. This may result in part from the relatively prolonged survival of F1+2 in the human circulation as compared with FPA (12) or PCP (8) . However, it is likely that a more rapid in vivo neutralization rate for thrombin vis a vis Factor Xa also contributes to the disparate increase in the levels of F1+2 as compared with FPA or PCP (7).
To identify subsets of aging patients with a common molecular basis for hemostatic system hyperactivity, we have analyzed the results in Normative Aging Study participants with high and low values in the F1+2, FPA, and PCP RIAs. In a subgroup of 53 patients with F1+2 measurements that were either > 2.5 nM (mean F1+2, 3 It therefore appears that a cohort of older males exhibits hemostatic system hyperactivity either on the basis of suppression of the endogenous heparin-antithrombin III mechanism without reduction in plasma concentration of the protease inhibitor, or excessive generation of Factor Xa that cannot be contained by this mucopolysaccharide-dependent natural anticoagulant mechanism. The decreased activity of the heparin-antithrombin III mechanism could be secondary to low levels of vessel wall heparinlike substances and/or more effective competition between blood components and antithrombin III for the limited quantities of endothelial cell glycosaminoglycan. In this regard, it is interesting to note that the incidence of thromboembolic disease in patients with congenital deficiencies of antithrombin III or protein C increases substantially with advancing age (37, 38) . A further reduction in the functional activity of these anticoagulantly active heparinlike molecules with the normal aging process might explain this clinical observation. The increased generation of Factor Xa in our population of aging males could also be due to greater exposure of tissue factor with subsequent activation of Factor VII as a consequence of the presence of occult vascular disease.
The elucidation ofthe molecular basis for the emergence of an age-dependent hypercoagulable state will require additional research. Recent studies have provided evidence that cultured fibroblasts synthesize heparinlike molecules that exhibit anticoagulant activity (39) . This system may provide a useful model for studying defects of this component of the vascular endothelium in patients undergoing the aging process. Biochemical markers such as the F1+2 assay which are able to reflect dysfunction of these natural anticoagulant mechanisms might then be used to develop therapeutic strategies to correct these derangements and hopefully prevent the onset of vascular disease.
